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Abstract 
Purpose: The aim of the study was to analyze early mortality after continuous-flow left ventricular assist device 
(LVAD) implantation which remains high.
Methods: We analyzed consecutive (n = 2689) patients from the European Registry for Patients with Mechanical 
Circulatory Support (EUROMACS) undergoing continuous-flow LVAD implantation. The primary outcome was early 
(< 90 days) mortality. Secondary outcomes were differential causes of early post-operative death following LVAD 
implantation.
Results: Univariable and multivariable analysis as well as regression analysis were used to examine determinants and 
differential causes of early (< 90 days) mortality after LVAD implantation. During the first 90 days, 2160 (80%) patients 
were alive with ongoing LVAD support, 40(2%) patients underwent heart transplantation, and 487(18%) deceased. The 
main causes of early death were MOF (36%), sepsis (28%), cardiopulmonary failure (CPF; 10%), CVA (9%), and right-
sided heart failure (RHF, 8%). Furthermore, MOF and sepsis are 70% of causes of death in the first week. Independent 
clinical predictors of early death were age, female sex, INTERMACS profile 1 to 3, and ECMO. Laboratory predictors 
included elevated serum creatinine, total bilirubin, lactate, and low hemoglobin. Furthermore, hemodynamic predic-
tors included elevated RA-to-PCWP ratio, pulmonary vascular resistance, and low systemic vascular resistance. Longer 
total implantation time was also independent predictor of early mortality. A simple model of 12 variables predicts 
early mortality following LVAD implantation with a good discriminative power with area under the curve of 0.75.
Conclusions: In the EUROMACS registry, approximately one out of five patients die within 90 days after LVAD 
implantation. Early mortality is primarily dominated by multiorgan failure followed by sepsis. A simple model identifies 
important parameters which are associated with early mortality following LVAD implantation.
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Introduction
Continuous-flow left ventricular assist devices (LVADs) 
are increasingly used for treating patients with end-
stage heart failure as a bridge to cardiac transplantation 
(HTx) or as a destination therapy (DT). Compared with 
medical therapy, LVAD implantation has reduced death 
and improved quality of life [1–3]. Current state-of-the-
art devices are promising in terms of improved survival 
and lower morbidity rates [4]. However, early post-LVAD 
mortality remains high [5–8]. Furthermore, causes and 
determinants of death following LVAD implantation are 
not well described for the European population. In small 
series, high post-LVAD mortality is associated with acute 
kidney injury (AKI) and multi-organ failure [9, 10]. There 
are few data on predictors of early ICU death (≤ 90 days) 
after LVAD implantation [11].
Therefore, we aimed to investigate the causes of death 
early after LVAD implantation. Furthermore, we sought 
to explore predictors of early death using multivariate 
analysis. The preliminary result of this study is partly pre-
sented at the scientific sessions of the European Society 
of Cardiology Congress [12].
Methods
Study population
All consecutive patients treated with mainstream contin-
uous-flow LVAD devices (i.e., HeartMate II, HeartWare, 
and HeartMate 3) from EUROMACS, a Registry of the 
European Association for Cardio-Thoracic Surgery, from 
January 2006 until May 2017 were included. All partici-
pating hospitals sign a contract with the EUROMACS 
Registry. In the contract, it is agreed that patients are 
sufficiently informed about the treatment that they are 
to undergo, including the risk of complications and mor-
tality. The Registry contains data for scientific analyses, 
and is aimed at improving care of patients with end-
stage heart failure (HF) who need mechanical circulatory 
support [13]. All relevant clinical, echocardiographic, 
hemodynamic, and laboratory characteristics were pro-
spectively collected by participating EUROMACS sites 
and entered into an electronic database (see appendix 
Table  1 for the list of EUROMACS sites and investiga-
tors (alphabetical according to country). To ensure the 
best quality of data and to exclude the underreporting 
of poor outcomes, the EUROMACS Registry applies 
several methods. Incoming data are analyzed on a regu-
lar basis. Individual hospitals are approached, and guid-
ance is offered to complete or correct their data. Entries 
are adapted to adhere to the standard. Twice a year, each 
center receives a file in which an overview of patients 
whose statuses need to be updated and whose changes/
answers have to be monitored is presented. Statistical 
consistency and plausibility checks are performed, and 
the records containing the inconsistent data of the partic-
ipating centers are identified. Data that are not plausible 
require checking and confirmation by the participating 
centers. Details of the Registry and data collection are 
described elsewhere [13]. This study was approved by the 
local institutional review committee and all subjects pro-
vided informed consent.
Study outcome
We defined early mortality as death within 90 days after 
LVAD implantation. The EUROMACS registry protocol 
mandates sites to report death using a list of 17 causes of 
death as follows: multi-organ failure (MOF), cerebro-vas-
cular accident (CVA), sepsis, infection, bleeding, cardio-
pulmonary failure (CPF), right-sided heart failure (RHF), 
device failure, lung failure, myocardial infarction, suicide, 
cancer, left heart failure, pulmonary artery embolism, 
trauma, other causes of death, and unknown cause of 
death. MOF implies usually two or more organs’ dysfunc-
tion at the same time. We combined sepsis and infection 
into sepsis as main cause of death. Similarly, cardiopul-
monary failure, left heart failure, lung failure, pulmonary 
artery embolization, and myocardial infarction into car-
diopulmonary failure (CPF). Right-sided heart failure 
(RHF) as directly related to death was documented inde-
pendently, when RHF does not lead to MOF or sepsis 
[14, 15]. Therefore, we created eight dominant causes of 
death including sepsis, MOF, CVA, CPF, bleeding, RHF, 
device failure, and others. Other causes of death included 
cancer, suicide, trauma, and all other than main causes of 
death.
Potential predictors of early mortality
We examined potential pre-operative characteristics as 
well as surgical and cardiopulmonary bypass (CPB) time 
for the association with early mortality. Pre-operative 
clinical data included age, gender, body surface area, 
body mass index, and blood type, HF etiology, NYHA 
functional profile, and INTERMACS profile were taken 
into account [16]. The pre-operative use of ≥ 3 intrave-
nous inotropes as well as the use of vasopressors were 
included. Furthermore, LVAD device strategy such as DT, 
Take‑home message 
Eighteen percent of patients in the EUROMACS registry died within 
90-days following LVAD implantation.
Early mortality after LVAD implantation is primarily dominated by 
multiorgan failure followed by sepsis.
A simple model of 12 variables predicts early mortality following 
LVAD implantation with a good discriminative power with area 
under the curve of 0.75.
use of intra-aortic balloon pump (IABP), and extracor-
poreal membrane oxygenator (ECMO) were additionally 
included. Pre-operative echocardiographic characteris-
tics were recorded and analyzed in accordance with pub-
lished guidelines [17, 18] including tricuspid annular 
plane systolic excursion (TAPSE), RV dysfunction on vis-
ual score, LV ejection fraction (LVEF), and mitral, aortic, 
and tricuspid valvular regurgitation. Median duration of 
echocardiographic data collection before LVAD surgery 
was 6 days. Severity of valvular regurgitation was graded 
as none, trivial, mild, moderate, and severe according to 
published guidelines [19, 20].
Hemodynamic predictors included heart rate, sys-
tolic and diastolic blood pressure, as well as Swan-Ganz 
recordings. The latter included systolic, diastolic and 
mean pulmonary artery (PA) pressure, right atrial (RA) 
pressure, pulmonary capillary wedge pressure (PCWP), 
pulmonary (PVR) and systemic (SVR) vascular resistance, 
and cardiac index. The PVR is calculated as transpul-
monary gradient (TPG) divided by the cardiac output 
(CO), which has a normal value of < 3 Wood units (or 240 
dynes·sec·cm−5). TPG was calculated as the difference 
between the PA mean pressure and PCWP. The ratio of 
RA to PCWP and PA pulsatility index (PAPi) [21] were 
also calculated. The RV systolic work index (RVSWI) was 
calculated as RV stroke volume index × (mean PA pres-
sure  −  central venous pressure)  ×  0.0136 expressed in 
gm/m2/beat were calculated. The factor 0.0136 was used 
to covert pressure (mmHg) into work (g/m2). Normal val-
ues are 5–10 g/m2/beat.
Laboratory characteristics included serum sodium and 
potassium levels, renal function parameters including 
blood urea nitrogen, serum creatinine levels, and liver 
function parameters including AST, LDH, total bilirubin, 
and serum albumin level. In addition, white blood count, 
platelets count, INR, APTT, lactate, and hemoglobin lev-
els were also included.
Statistical analysis
Patient characteristics are described as means (standard 
deviation [SD]) or medians (interquartile range [IQR]) 
for continuous variables and frequency (percentage) for 
categorical variables. Differences between patient groups 
are evaluated for continuous variables by the Student 
t tests (Gaussian distribution) or the non-parametric 
Mann–Whitney U tests (non-Gaussian distribution) and 
the categorical variables using the Chi-square test.
Univariate logistic regression analysis was applied to 
relate a broad range of pre-operative parameters with the 
study outcome, including demographics, clinical, medica-
tions, echocardiographic, hemodynamic, and laboratory 
characteristics. Variables with a p value < 0.20 entered 
the multivariate stage, and a multivariate regression 
model was constructed to predict early mortality follow-
ing LVAD implantation, applying the stepwise forward 
method, with a p = 0.05 model-entry criterion.
For the main causes of death, we calculated and 
reported the frequencies for early mortality in time-
based analysis beginning from the day of implantation 
till 30  days and between 30 and 90  days. We reported 
the cumulative early mortality. Multiple imputations 
were used to account for randomly missing values after 
examining the pattern of missing values as described 
before [14]. We accepted the missing data for < 20% of in 
the entire population. The goodness-of-fit of the logistic 
regression model was measured in terms of its calibra-
tion. Calibration, which measures the ability of the model 
to fit the data, was tested with the Hosmer–Lemeshow 
statistic.
A two-tailed p < 0.05 was considered statistically sig-
nificant, and all statistics were undertaken using the SPSS 
statistics version 24 (IBM corporation, NY, USA), Med-
Calc (Statistical MedCalc Software, Ostend, Belgium), 
and the R-statistical package.
Results
Study cohort
Between January 1, 2006, and May 31, 2017, a total of 
2988 adult patients who underwent continuous-flow 
LVAD implantation with mainstream devices (Heart-
Ware, HeartMate II, or HeartMate 3) were included. 
We excluded patients missing data about the brand type 
of LVAD (n = 35) and missing follow-up data (n = 264) 
(Fig.  1). The final study population comprised 2689 
patients with a mean age of 53 ± 13 years and 472 (18%) 
women (Table  1); the majority were Caucasians (66%, 
n = 1785). The main etiology of HF was non-ischemic 
(67%, n = 1807). The main indications for LVAD implan-
tation were bridge to candidacy (44%, n = 1001), fol-
lowed by BTT (29%, n = 655). Mainstream devices were 
HeartWare® HVAD as the most used LVAD brand (51%, 
n = 1369), followed by HeartMate II® (43%, n = 1167) and 
HeartMate 3® (6%, n = 153).
Post LVAD outcome
During follow-up duration of 90  days, out of 2689 
patients, 487 (18%) were deceased; 40(2%) were trans-
planted; in 2 (0.1%), the device was explanted; and 2160 
(80%) were alive on LVAD support (Fig. 1). Differences in 
key baseline and peri-operative characteristics between 
survivors and non-survivors are shown (Table 1).
Time course of death after LVAD implantation
Overall, primary causes of death were sepsis (28%), 
MOF (26%), and CVA (15%). Furthermore, MOF (36%), 
sepsis (28%), and CPF (10%) were the main primary 
causes of death followed by CVA (9%) and RHF (8%) in 
the early (≤ 90 days) after LVAD implantation (Fig. 2).
Differential causes of death within 90 days following LVAD 
implantation
In-depth daily or weekly analysis of the differential 
causes of death in the early 90  days following LVAD 
implantation revealed MOF as the main cause of death 
in 40–50% the first 2 weeks and decreased to approxi-
mately 10% of total causes of death thereafter. In con-
trast sepsis is seen in day one as 10% of causes of death, 
increased to 20–40% thereafter. CPF occurred in 20% at 
the day of LVAD implantation and decreased to 5% or 
less thereafter. CVA was seen as 20% of causes of death 
on the day of LVAD implantation, 5–10% between day 1 
to 90 days. Bleeding as a cause of death was seen in 20% 
of causes of death during day one after LVAD implanta-
tion, < 5% between day 2 and 90 days. RHF as a cause of 
death was seen in approximately 20% of causes of death 
during day 1 after LVAD implantation. Device failure 
was not seen as a cause of death in the first 90 days.
As seen on Fig. 2, only nine subjects in the study died 
on the day of operation and 16 subjects died in the first 
day after the operation. Known causes of death on the 
operation day were cerebro-vascular accident in one 
patient, multi-organ failure in two, cardiopulmonary 
failure in one, and other cause of death in one patient,
In the day after LVAD implantation, known causes of 
death were MOF in eight patients, RHF in three, bleed-
ing in three, CVA in one, and sepsis in one were seen.
Predictors of early mortality post‑LVAD
Univariate exploratory analysis as well as multivariable 
model of the independent predictor of early mortality 
following LVAD implantation are seen in Tables 1 and 
2. Exploratory univariate logistic regression analysis for 
early mortality following LVAD implantation yielded 49 
potential covariates (p < 0,20) out of 59 tested variables, 
as clinical, medication, laboratory, echocardiographic, 
hemodynamic, and operative covariates (Table 2). Inde-
pendent clinical predictors of early death were age (OR 
1.028, 95% CI 1.018–1.038) female sex (OR 1.339, 95% 
CI 1.003–1.788), INTERMACS profile 1 to 3 (OR 1.500, 
95% CI 1.121–2.007), and ECMO (OR 1.989, 95% CI 
1.431–2.765). Laboratory predictors included elevated 
serum creatinine (OR 1.003, 95% CI 1.002–1.005), total 
bilirubin (OR 1.193, 95% CI 1.116–1.275), lactate (OR 
1.011, 95% CI 1.003–1.019), and low hemoglobin (OR 
0.908, 95% CI 0.858–0.961). Furthermore, hemody-
namic predictors included elevated RA-to-PCWP ratio 
(OR 1.740, 95% CI 1.292–2.344), pulmonary vascular 
resistance (OR 1.089, 95% CI 1.044–1.135), and low 
systemic vascular resistance (OR 0.974, 95% CI 0.957–
0.992). Longer total implantation time (OR 1.003, 95% 
CI 1.002–1.004) was also independent predictor of 
early mortality (Table 3).
ROC analysis of the two multivariable models yielded 
a predictive discriminative value of 0.75 (Fig.  3). Fur-
thermore, the model had a good calibration by the 
Hosmer–Lemeshow statistic (Chi-square value, 8.38, p 
value: 0.40).
Fig. 1 Flowchart of the study population. This flowchart describes the outcome in total population of EUROMACS over follow-up of 90 days. 
EUROMACS The European Registry for Patients with Mechanical Circulatory Support, LVAD left ventricular assist device
Table 1 Baseline and peri‑operative characteristics of patients undergoing continuous‑flow LVAD implantation
Variables Total population 
(N = 2689)
Survivors 90 days 
(n = 2202)
Non‑survivors 90 days 
(n = 487)
p value
Demographics
 Age, year 53 ± 13 52 ± 12 55 ± 13  < 0.001
 Gender (Female), n (%) 472 (18) 373 (17) 99 (20) 0.08
 Body surface area,  m2 1.96 ± 0.23 1.96 ± 0.23 1.96 ± 0.26 0.66
 Body mass index, kg/m2 26.1 ± 5 26 ± 4.8 26.7 ± 5.6 0.01
 Ischemic etiology, n (%) 882 (33) 704 (32) 178 (37) 0.06
 Blood type O, n (%) 1010 (38) 823 (37) 187 (38) 0.68
 INTERMACS class, n (%)  < 0.001
  1 297 (11) 182 (8) 115 (24)
  2 854 (32) 663 (30) 191 (39)
  3 693 (26) 610 (28) 83 (17)
  ≥ 4 737 (27) 653 (30) 84 (17)
 IABP, % 246 (9) 185 (8) 61 (13) 0.01
 VA-ECMO, % 249 (9) 101 (5) 148 (30)  < 0.001
 NYHA functional class, n (%) 0.001
  III 838 (31) 715 (32) 123 (25)
  IV 1110 (41) 875 (40) 235 (48)
 Intravenous medication, n (%)
  Use of vasopressors 574 (21) 381 (17) 193 (40)  < 0.001
  Use of inotropes ≥ 3 340 (13) 243 (11) 97 (20)  < 0.001
Laboratory
 Serum creatinine, mg/dL 1.17 [0.96–1.5] 1.15 [0.95–1.43] 1.29 [1.06–1.84]  < 0.001
 BUN, mg/dL 48 [34–74] 46 [32–68] 63 [40–97]  < 0.001
 AST, U/L 31 [22–64] 30 [21–53] 46 [25–187]  < 0.001
 LDH, U/L 340 [257–489] 334 [252–474] 364 [271–591]  < 0.001
 Total bilirubin, mg/dL 1.32 [0.83–2.05] 1.27 [0.8–1.9] 1.64 [1.1–2.6]  < 0.001
 WBC,  109/mL 8.2 [6.5–10.7] 8 [6.4–10.3] 9.3 [6.9–12.6]  < 0.001
 Platelets, 1000/mL 207 [158–252] 211 [170–254] 179 [116–240]  < 0.001
 INR 1.3 [1.1–1.6] 1.24 [1.1–1.5] 1.39 [1.2–1.8]  < 0.001
 aPTT, sec 39 [32–47] 39 [32–46] 42 [34–53]  < 0.001
 Lactate, mmol/L 1.5 [1.1–2.3] 1.4 [1–2.1] 1.6 [1.1–3.5]  < 0.001
 Albumin, mg/dL 3.9 [3.3–5.2] 3.9 [3.4–5.2] 3.6 [3.2–4.7]  < 0.001
 Hemoglobin, g/dL 12.1 [10.5–13.9] 12.4 [10.8–14] 10.9 [9.8–12.7]  < 0.001
Hemodynamic
 Heart rate, beats/min 85 [74–98] 84 [74–98] 88 [75–101] 0.01
 Diastolic BP, mmHg 65 [59–71] 65 [60–72] 62 [55–70] 0.07
 Systolic BP, mmHg 100 [90–110] 100 [90–110] 100 [88–110] 0.07
 RA pressure, mmHg 11 [8–15] 10 [7–14] 13 [9–17]  < 0.001
 PCWP, mmHg 24 [18–29] 24 [29] 25 [29] 0.32
 PAP systolic 52 [41–63] 53 [41–63] 52 [40–62] 0.37
 PAP diastolic 26 [20–32] 26 [20–32] 26 [21–32] 0.72
 PAP mean, mmHg 35 [28 – 42] 35 [28–42] 35 [27–42] 0.82
 CO, L/min 3.6 [3.0–4.4] 3.6 [2.9–4.4] 3.6 [2.9–4.4] 0.08
 CI, L/min/m2 1.9 [1.5–2.2] 1.9 [1.5–2.2] 1.9 [1.6–2.3] 0.07
 RVSWI, g/m2/beat 6.7 [5.1 – 9.3] 6.3 [4.6–8.9] 6.9 [5.2– 9.4]  < 0.001
 SVR, Woods units 18.2 [14.2–23] 17.9 [13.6–23.4] 15.7 [11.9–20.3]  < 0.001
 PVR, Woods units 2.9 [1.6—4.8] 3.2 [2.1–4.5] 3.3 [2–4.7] 0.08
 RA/PCWP 0.46 [0.33–0.65] 0.45 [0.32–0.63] 0.52 [0.38–0.75]  < 0.001
 PAPi 2.4 [1.54–3.69] 2.5 [1.62–3.89] 2 [1.33–3.1]  < 0.001
Discussion
To the best of our knowledge, this is the first and larg-
est study to explore differential causes of death in the 
early (90 days) post-LVAD in Europe. Earlier Intermacs 
annual reports described an early rapidly falling hazard 
phase merges with a constant phase at approximately 
3 months [22]. The main study findings are: (1) 18% of 
LVAD recipients died within 90  days following LVAD 
implantation; (2) MOF and sepsis followed by CPF and 
CVA are the most common causes of death in the early 
period; (5) A simple model of 12 variables predicted 
early mortality following LVAD implantation with a 
good discriminative power with area under the curve of 
0.75.
Independent clinical predictors of early death were age, 
female sex, INTERMACS profile 1 to 3, and ECMO. Lab-
oratory predictors included elevated serum creatinine, 
total bilirubin, lactate, and low hemoglobin. Further-
more, hemodynamic predictors included elevated RA-
to-PCWP ratio, pulmonary vascular resistance, and low 
systemic vascular resistance. Longer total implantation 
time was also independent predictor of early mortality.
The common causes of death were MOF, CVA, and sep-
sis, followed by RHF and device malfunction in the early 
90  days in the INTERMACS registry [22]. Among the 
three mainstream LVAD brands used in this study, CVA 
has been shown more frequently in HVAD compared 
with HMII [23]. Furthermore, the use of latest LVAD 
designs such as HM3 in the MOMENTUM 3 study was 
associated with less frequent thromboembolic complica-
tions than HMII [24, 25]. In our study of EUROMACS 
Registry, the main causes of early death were MOF (36%), 
sepsis (28%), cardiopulmonary failure (CPF; 10%), CVA 
(9%), and right-sided heart failure (RHF, 8%). Further-
more, MOF and sepsis are 70% of causes of death in the 
first week.
The cascade of RHF-induced cardiogenic shock, acute 
kidney failure, and MOF provokes high morbidity and 
mortality, including prolonged ICU stay and hospitali-
zation. Congestion and/or ischemia of the gastrointes-
tinal tract, particularly when associated with prolonged 
ICU stay, predisposes to bacterial translocation. In this 
study, 26% of deaths are due to sepsis with similar inci-
dence in the early period following LVAD implantation. 
Table 1 (continued)
Variables Total population 
(N = 2689)
Survivors 90 days 
(n = 2202)
Non‑survivors 90 days 
(n = 487)
p value
Echocardiographic
 Severe RV dysfunction, n (%) 257 (10) 179 (8) 78 (16)  < 0.001
 TAPSE, mm/s 14 [5–30] 14 [5–30] 14 [7–29] 0.48
 Moderate-to-severe tricuspid regurgitation, n (%) 271 (10) 534 (36) 388 (41) 0.93
 Moderate-to-severe mitral regurgitation, n (%) 36 (2) 674 (56) 377 (44) 0.51
 Moderate-to-severe aortic regurgitation, n (%) 128 (6) 45 (4) 40 (5) 0.001
 LV-EF grade < 20%, n (%) 1045 (53) 831 (38) 214 (44) 0.19
 Main LVAD strategy  < 0.001
  BTT (on the list) 655 (29) 462 (35) 193 (20)
  BTC 1001 (44) 573 (44) 428 (45)
  Destination therapy 441 (19) 187 (14) 254 (27)
  Rescue therapy 130 (6) 65 (5) 65 (7)
  BTR and others 44 (2) 25 (2) 19 (2)
 LVAD device brand, n (%)
  HeartMate II 1167 (43) 1033 (47) 134 (28)  < 0.001
  HeartMate 3 153 (6) 112 (5) 41 (8)  < 0.001
  Heart Ware HVAD 1369 (51) 1057 (48) 312 (64) 0.007
 Surgical duration
  CPB time, min 86 [65–15] 86 [64–113] 91 [61–133]  < 0.001
  Surgery time, min 230 [180–285] 225 [180–277] 255 [193–330]  < 0.001
All continuous values are presented in mean ± standard deviation unless stated otherwise or presented as median [IQR]. Categorical variables are stated as 
frequencies and percentages.
AST serum aspartate transaminase, IABP intra-aortic balloon pump, INTERMACS the Interagency Registry for Mechanically Assisted Circulatory Support (For INTERMACS 
classes. see text for details), LV left ventricular, EF ejection fraction, LVAD left ventricular assist device, VA-ECMO veno-arterial extracorporeal membrane oxygenator, 
NYHA New York Heart Association, PAP pulmonary artery pressure, PAPi pulmonary artery pulsatility index, PCWP pulmonary capillary wedge pressure, PVR pulmonary 
vascular resistance, RA right atrial, RV right ventricular, RVSWI right-ventricular stroke work index, TAPSE tricuspid annular plane systolic excursion, BTT bridge to 
transplant, BTC bridge to candidacy, BTR bridge to recovery, CPB cardio pulmonary bypass
Infections are either VAD-specific, VAD-related, and/or 
non-VAD infections. Despite improved care, driveline 
infections are associated with high morbidity and mor-
tality [26–28]. As abovementioned, prolonged ICU stay is 
associated with increased risk of infection consequently 
impacting survival post-LVAD [14].
Components of predicting early mortality
In our study, the predictors for early post-LVAD mor-
tality are: older age, female sex, sicker, hospitalized 
patients (INTERMACS profile 1 to 3 and having ECMO), 
impaired renal and hepatic function (serum creatinine 
and total bilirubin), prolonged tissue hypoxia (lactate), 
and low hemoglobin. Furthermore, hemodynamic pre-
dictors included elevated RA-to-PCWP ratio, pulmonary 
vascular resistance, and low systemic vascular resist-
ance reflecting right-sided heart failure. Prolonged total 
implantation time is associated with early mortality.
Our findings confirm also the role of advanced age and 
female sex as predictors of increased early mortality fol-
lowing LVAD implantation [22, 29].
High RA/PCWP is a sign of RHF, mostly in com-
bination with volume overload. Aggressive pre- and 
post-operative diuresis for euvolemia, prolonged post-
operative inotropic support, pulmonary vasodilators 
(e.g., nitric oxide, inhaled prostacyclin), and, in selected 
case, temporary RVAD support could help to prevent 
further complications of severe RHF. Furthermore, 
elevated PVR is associated with increased early death. 
High PVR contribute to RV afterload and decreased RV 
function. If the pulmonary artery compliance does not 
improve rapidly, post-LVAD risk of RHF increases [14, 
21, 30]. LVAD implantation will usually improve the RV 
function, the pulmonary and LV filling pressures. In the 
very, early post-operative phase, however, the RV needs 
time (probably > 10–14  days) before physiological adap-
tation and recovery of the peri-operative hit of ischemia, 
distorted interventricular dependence, and volume over-
load will commence.
Our findings confirm that an advanced INTERMACS 
profile is associated with increased early mortality fol-
lowing LVAD implantation [31]. Patients with advanced 
INTERMACS profile are sicker, have a higher incidence 
of biventricular failure, suffer from severe hemodynamic 
derangement with imminent secondary organ / multi-
organ failure [32]. However, in a recent trial, the early 
LVAD implantation in higher INTERMACS profiles 
(5–7) except for profile 4 failed to be superior to medical 
therapy, especially in terms of survival and quality of life 
[33].
Patients presenting with acute “crush and burn” need 
stabilization with a temporary MCS before commenc-
ing to a durable MCS. However, currently available tem-
porary MCS, such as VA-ECMO, Impella, and IABP, 
in patients in INTERMACS 1 results in poor outcome 
post-LVAD and, therefore, yet to be further explored 
Fig. 2 Detailed time-based presentation of causes of death within 90 days following LVAD implantation in the EUROMACS registry. For abbrevia-
tions, see Fig. 1
Table 2 Baseline univariate predictors of early mortality after LVAD implantation using continuous values
Variables Coefficient 
of regression
S.E Wald p value OR Lower 95.0% CI 
for OR Lower
Upper 95.0% CI 
for OR Upper
Demographics
 Age, year 0.023 0.004 29  < 0.001 1.023 1.015 1.032
 Gender (female) 0.224 0.126 3 0.076 1.251 0.977 1.602
 Body surface area,  m2 − 0.101 0.228 0.197 0.657 0.904 0.578 1.414
 Body mass index, kg/m2 0.006 0.006 0.844 0.358 1.006 0.994 1.017
 Race (Caucasian) 0.461 0.113 16.657  < 0.001 1.585 1.271 1.978
 Ischemic aetiology 0.204 0.105 3.786 0.052 1.226 0.999 1.505
 Blood type O (reference) 0.202 1 – –
 Blood type A 0.047 0.111 0.177 0.674 1.048 0.844 1.301
 Blood type AB − 0.212 0.232 0.833 0.361 0.809 0.513 1.275
 Blood type B − 0.270 0.166 2.658 0.103 0.763 0.551 1.056
 INTERMACS class (1–3 vs 4–7) 0.732 0.129 32.06  < 0.001 2.078 1.613 2.677
 IABP (yes vs no) 0.374 0.158 5.581 0.018 1.454 1.066 1.984
 VA-ECMO (yes or no) 1.291 0.141 84.176  < 0.001 3.635 2.759 4.790
 Use of vasopressors 1.082 0.113 91.937  < 0.001 2.950 2.365 3.680
 Use of inotropes ≥ 3 0.6 0.134 19.891  < 0.001 1.821 1.399 2.371
Laboratory
 Serum creatinine, mol/L 0.006 0.001 61.481 0.000 1.006 1.005 1.008
 BUN, mg/dL 0.008 0.001 3.117  < 0.001 1.008 1.006 1.011
 AST U/L 0.000 0.000 27.100  < 0.001 1.000 1.000 1.000
 AST > 37 U/L 0.776 0.111 48.53  < 0.001 2.173 1.747 2.704
 LDH U/L 0.000 0.000 1.138  < 0.001 1.000 1.000 1.000
 LDH > 445 U/L 0.762 0.131 33.978  < 0.001 2.143 1.658 2.768
 Total bilirubin, mg/dL 0.254 0.032 63.348  < 0.001 1.289 1.211 1.372
 WBC, 109/mL 0.061 0.010 34.632  < 0.001 1.063 1.041 1.084
 Platelets, 1000/mL − 0.004 0.001 35.907  < 0.001 0.996 0.994 0.997
 Platelets > 138, 1000/mL 0.921 0.119 59.427  < 0.001 2.512 1.987 3.175
 INR 0.264 0.060 19.253  < 0.001 1.302 1.157 1.465
 PTT, sec 0.008 0.002 14.361  < 0.001 1.009 1.004 1.013
 Lactate, mmol/L 0.015 0.004 17.724  < 0.001 1.016 1.008 1.023
 Albumin, mg/dL − 0.022 0.013 2.912 0.088 0.978 0.954 1.003
 Hemoglobin, g/dL − 0.177 0.026 47.489  < 0.001 0.838 0.797 0.881
Hemodynamic
 Heart rate, beats/min 0.007 0.003 6.045 0.014 1.007 1.001 1.012
 Heart rate > 100 beats/min 0.352 0.125 7.906 0.005 1.423 1.113 1.819
 Diastolic BP, mmHg − 0.02 0.005 18.695  < 0.001 0.980 0.972 0.989
 Systolic BP, mmHg − 0.006 0.003 3.361 0.067 0.994 0.988 1.000
 RA pressure, mmHg 0.062 0.009 48.111  < 0.001 1.064 1.045 1.083
 PCWP, mmHg 0.007 0.007 1.005 0.316 1.007 0.994 1.020
 PAP systolic − 0.003 0.003 0.817 0.366 0.997 0.991 1.003
 PAP diastolic 0.002 0.005 0.132 0.716 1.002 0.992 1.012
 PAP mean, mmHg − 0.001 0.005 0.053 0.817 0.999 0.990 1.008
 PAPi − 0.126 0.027 21.731  < 0.001 0.882 0.837 0.930
 CO, L/min 0.075 0.043 3.013 0.083 1.078 0.990 1.174
 CI, L/min/m2 0.142 0.079 3.235 0.072 1.153 0.987 1.346
 RVSWI, g/m2/beat − 0.063 0.017 13.755  < 0.001 0.939 0.908 0.971
 SVR, woods units − 0.038 0.008 21.820  < 0.001 0.963 0.948 0.978
 PVR, woods units 0.033 0.019 3.065 0.080 1.033 0.996 1.072
 RA/PCWP 0.648 0.139 21.753  < 0.001 1.912 1.456 2.511
[16]. Furthermore, patients with pre-operative impaired 
renal and hepatic function, or prolonged peripheral tis-
sue hypoxia (lactate) have increased early mortality fol-
lowing LVAD implantation. We believe that proper 
timing of LVAD, earlier in the process of end-stage heart 
failure, before a full-blown cardiogenic shock, is criti-
cal in achieving a good survival chance. Furthermore, 
Table 2 (continued)
Variables Coefficient 
of regression
S.E Wald p value OR Lower 95.0% CI 
for OR Lower
Upper 95.0% CI 
for OR Upper
Echocardiographic
 Severe RV dysfunction 0.600 0.139 18.476  < 0.001 1.821 1.386 2.394
 TAPSE, mm/s − 0.011 0.016 0.499 0.480 0.989 0.959 1.020
 Moderate or severe tricuspid regurgitation 0.271 0.107 6.476 0.011 1.312 1.064 1.616
 Moderate or severe tricuspid regurgitation − 0.030 0.168 0.032 0.857 0.970 0.699 1.348
 Moderate or severe mitral regurgitation 0.260 0.404 0.414 0.520 1.297 0.587 2.863
 Moderate or severe aortic regurgitation 0.686 0.200 11.732 0.001 1.986 1.341 2.941
 LV-EF grade < 20% 0.152 0.114 1.764 0.184 1.164 0.930 1.457
Operative and/or device variables
 Main LVAD strategy
  BTT (on the list) 40.523  < 0.001 Reference
  BTC 0.286 0.140 4.173 0.041 1.331 1.012 1.752
  Destination therapy 0.806 0.156 26.605  < 0.001 2.238 1.648 3.040
  Rescue therapy 1.013 0.221 21.008  < 0.001 2.755 1.786 4.248
  BTR and others 0.843 0.357 5.585 0.018 2.324 1.155 4.678
 Surgical duration
  Surgery time, min 0.003 0 50.574  < 0.001 1.003 1.002 1.004
AST serum aspartate transaminase, IABP intra-aortic balloon pump, INTERMACS the Interagency Registry for Mechanically Assisted Circulatory Support (For INTERMACS 
classes. see text for details), LV left ventricular, LVAD left ventricular assist device, VA-ECMO veno-arterial extracorporeal membrane oxygenator, NYHA New York Heart 
Association, PAP pulmonary artery pressure, PAPi pulmonary artery pulsatility index, PCWP pulmonary capillary wedge pressure, PVR pulmonary vascular resistance, 
RA right atrial, RV right ventricular, RVSWI right-ventricular stroke work index, TAPSE tricuspid annular plane systolic excursion, BTT bridge to transplant, BTC bridge to 
candidacy, BTR bridge to recovery, CPB cardio pulmonary bypass
Table 3 Baseline multivariate predictors of early mortality 
after LVAD implantation using continuous values
For abbreviations, see Table 1
Variables OR 95.0% CI for OR p value
Age (years) 1.028 1.018–1.038 0.000
Gender (female) 1.339 1.003–1.788 0.048
INTERMACS Class 1–3 1.5 1.121–2.007 0.006
ECMO 1.989 1.431–2.765 0.000
Creatinine µmol/L 1.003 1.002–1.005 0.000
Total bilirubin g/dL 1.193 1.116–1.275 0.000
Lactate mmol/L 1.011 1.003–1.019 0.008
Hemoglobin g/dL 0.908 0.858–0.961 0.001
RA/PCWP 1.74 1.292–2.344 0.000
PVR woods unit 1.089 1.044–1.135 0.000
SVR woods unit 0.974 0.957–0.992 0.004
Total implantation time (min) 1.003 1.002–1.004 0.000
Fig. 3 Comparison of goodness of fit between the multivariable 
models using continuous versus categorical values. Receiver-oper-
ating characteristic curves showing similar area under the curve of 
the two models in predicting early (< 90 day) death following LVAD 
implantation
appropriate and timely management of the right ven-
tricular failure, prevention of severe kidney failure, and 
multi-organ failure are essential for a successful LVAD 
implantation.
Low hemoglobin level is associated with increased early 
mortality. Anemia is found in about one-third of chronic 
HF patients, most commonly due to anemia of chronic 
disease and chronic renal failure. Also, impaired nutri-
tion, malabsorption due to congestion, abnormal produc-
tion of hepcidin, and reduced intracellular uptake of iron 
have been reported as causes of anemia in patients with 
HF [34, 35]. Therefore, anemia might reflect the severity 
of the illness pre-LVAD.
Finally, prolonged time of LVAD surgery is associated 
with increased early mortality following LVAD implanta-
tion. This finding has been also shown in previous study 
by our group in which prolonged surgery time is associ-
ated with increased early right-sided heart failure com-
plicating an ICU course [14].
Clinical implications
We found that the most common causes of death early 
post-LVAD are MOF, sepsis, and CPF. Patients dying 
early after LVAD implantation were older, often female, 
sicker (INTERMACS profile 1–3), suffering from pre-
operative anemia, impaired renal and liver function, 
and having signs of impending or evident RHF. Those 
patients with high RA/PCWP have probably already 
compromised RV function and higher risk of post-oper-
ative right-sided heart failure. It is known that half of ICU 
patients had a nosocomial infection and are, therefore, 
at a high risk for sepsis [36]. Furthermore, as abovemen-
tioned, congested gut has been identified as a source of 
infection and is a known sepsis triggering problem in 
ICU patients with MOF, due to translocation of gut flora 
into the bloodstream [36, 37].
Based on the two main causes of death in early post-
LVAD, MOF, and sepsis, we should encourage clinicians 
to prevent deterioration of the RV function. A tailored 
risk-based approach focused on prevention and timely 
management of pre- and post-operative RHF via pharma-
cological and/or temporary RVAD. A patient with a high 
risk for early mortality may benefit from early or prophy-
lactically short-term mechanical circulatory support, and 
above all aggressive pre- and post-operative optimization 
of the right-sided fillings pressures. Second, early deci-
sion of LVAD implantation could select patients with less 
sicker patients, increasing INTERMACS profile and risk 
of secondary organ failure.
Limitations
There are several limitations that should be acknowl-
edged in this study including the retrospective analysis. 
Multi-national, multicenter registry like EUROMACS 
Registry without yet formal financial and manpower 
reimbursement from the national health authorities, 
insurance, the incomplete, has inherent shortcomings, 
like missing data. Several parameters were incompletely 
collected in the database. Therefore, we used multiple 
imputations to account for randomly missing data. How-
ever, this approach is based on strong assumptions that it 
is not possible to verify.
An another important limitation was also the retro-
spective analysis of the EUROMACS database. Another 
important limitation was the clinical judgment of the 
primary cause of death by which in case of multi-organ 
failure or sepsis was based on clinician’s own decision per 
site. Similarly, cardiopulmonary failure, which contains 
left heart failure, lung failure, pulmonary artery emboli-
zation, and myocardial infarction, could be used in differ-
ent way from the centers with underspecifying diseases 
like acute respiratory distress syndrome (ARDS) as lung 
failure. Furthermore, without a central core laboratory 
analysis of the imaging data, it is presumptuous that 
all data are analyzed in accordance with the published 
guidelines. However, the site initiation/audit and the pro-
tocol of the EUROMACS registry require that the site 
investigators to perform their analysis according to the 
published guidelines.
Conclusions
In the European Registry for Patients with Mechani-
cal Circulatory Support, approximately one out of five 
patients died within 90  days following LVAD implanta-
tion. Early mortality is primarily dominated by multior-
gan failure followed by sepsis. A simple model comprises 
12 variables predicts early mortality following LVAD 
implantation with a good discriminative power of an area 
under the curve of 0.75.
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